Short description
GenVec is a biopharmaceutical company employing differentiated, proprietary technologies for the creation of therapeutics and vaccines.
Description
GenVec, Inc. (NASDAQ: GNVC) GenVec, Inc. is a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines. A key component of our strategy is to develop and commercialize our product candidates through collaborations. GenVec is working with leading companies and organizations such as Novartis, Merial, and the U.S. Government to support a portfolio of product programs that address the prevention and treatment of a number of significant human and animal health concerns. GenVec’s development programs address therapeutic areas such as hearing loss and balance disorders; as well as vaccines against infectious diseases including respiratory syncytial virus (RSV), herpes simplex virus (HSV), dengue fever, influenza, malaria, and human immunodeficiency virus (HIV). In the area of animal health we are developing vaccines against foot-and-mouth disease (FMD).
Last funding
Blurry Noaccess
Sign in for full access
Total funding
$$3123123
Sign in for full access
Location
Gaithersburg, Maryland, United States, North America
Founded on
January 1, 1992
Exited on
December 22, 2000
Went public on
December 22, 2000
Delisted on
January 24, 2017
Stock symbol
GNVC
Non-profit?
No
Acquired?
No
Employees count
11-50
Revenue range
$56378 - 90123
Sign in for full access
Investors
Uh Ohhhh
Sign in for full access